Byrd, K. M., Beckwith, C. G., Garland, J. M., Johnson, J. E., Aung, S., Cu-Uvin, S., Farmakiotis, D., Flanigan, T., Gillani, F. S., Macias-Gil, R., Mileno, M., Ramratnam, B., Rybak, N. R., Sanchez, M., Tashima, K., Mylonakis, E. and Kantor, R. SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J Int AIDS Soc. 2020; 23(7):e25573

1. INTRODUCTION {#jia225573-sec-0005}
===============

The first case of coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) was reported in Wuhan, China in December 2019 \[[1](#jia225573-bib-0001){ref-type="ref"}\]. Within months, the virus infected more than six million people, causing over 350,000 deaths worldwide. The first COVID‐19 case in the US was diagnosed on January 20, 2020, and as of June 02, the US leads the world in both COVID‐19 cases (1,857,872) and deaths (107,911) \[[2](#jia225573-bib-0002){ref-type="ref"}, [3](#jia225573-bib-0003){ref-type="ref"}\].

There are 37.9 million persons with HIV (PWH) globally, and 1.1 million in the US \[[4](#jia225573-bib-0004){ref-type="ref"}\]. PWH may be considered vulnerable to infections due to CD4 cell depletion. However, despite the large scale of the COVID‐19 pandemic, little is known about its characteristics in PWH. To date, there are only 158 confirmed HIV/SARS‐CoV‐2 coinfections reported in detail in the literature, nine from China \[[5](#jia225573-bib-0005){ref-type="ref"}, [6](#jia225573-bib-0006){ref-type="ref"}, [7](#jia225573-bib-0007){ref-type="ref"}, [8](#jia225573-bib-0008){ref-type="ref"}\], 56 from Spain \[[9](#jia225573-bib-0009){ref-type="ref"}, [10](#jia225573-bib-0010){ref-type="ref"}\], 33 from Germany \[[11](#jia225573-bib-0011){ref-type="ref"}\], 47 from Italy \[[12](#jia225573-bib-0012){ref-type="ref"}\] and 13 from the US \[[13](#jia225573-bib-0013){ref-type="ref"}, [14](#jia225573-bib-0014){ref-type="ref"}\] with diverse clinical severity and host characteristics including HIV‐related immunosuppression.

The first Rhode Island (RI) COVID‐19 case was diagnosed on 1 March, and as of 2 June, there were 15,441 cases (1.4% of the RI population) and 772 fatalities (4.9% of cases) \[[15](#jia225573-bib-0015){ref-type="ref"}\]. Of 1.06 million people in RI, approximately 2800 (0.3%) had HIV in 2018 \[[16](#jia225573-bib-0016){ref-type="ref"}\]. Uniquely, the Miriam Hospital Infectious Diseases and Immunology Center (the Center) cares for more than 80% of PWH who are in care in the state. Given limited knowledge of HIV/SARS‐CoV‐2 coinfection, in RI or elsewhere, and to better understand the impact of the COVID‐19 pandemic on PWH and improve their care, we present our outpatient and inpatient clinical experience.

2. METHODS {#jia225573-sec-0006}
==========

We first describe processes undertaken to achieve appropriate outpatient and inpatient preparedness for the COVID‐19 pandemic at The Miriam Hospital and RI Hospital, primary hospitals for the largest academic medical center in the state, and the Miriam Hospital Infectious Diseases and Immunology Center, in Providence, RI, US. We then present a case series of all known outpatients and inpatients with HIV/SARS‐CoV‐2 coinfection until the time of this writing. Medical records were reviewed for demographic, clinical, laboratory and outcomes data. The study was approved by, and a consent waiver was obtained from the Institutional Review Board at The Miriam Hospital in Providence, RI.

3. RESULTS AND DISCUSSION {#jia225573-sec-0007}
=========================

3.1. Outpatient preparedness {#jia225573-sec-0008}
----------------------------

The Center is a large, Ryan White‐funded HIV clinic, caring for more than 1800 patients; 98% meeting statewide income eligibility for financial assistance, and 76% reporting incomes below the federal poverty line. In 2019, 99% of Center patients were prescribed ART and 91% had HIV viral load (VL) \<200 copies/mL.

After the first COVID‐19 case in RI, the Center rapidly converted most patient visits to telehealth and deferred nonurgent laboratory testing. Understanding challenges PWH might face during social distancing, and realizing potential health consequences of changing insurance status due to job loss and furloughs, outreach‐worker staff proactively assist patients with insurance and medication access; the hospital pharmacy offers no‐charge home medication delivery; pharmacy liaisons assist with co‐pays; behavioral therapists use telehealth; and social workers address community challenges and evaluate and help to address food insecurities.

In regards to COVID‐19 testing and evaluation, the Center implemented a health‐system‐wide telehealth programme to evaluate suspected ambulatory COVID‐19 cases; completed construction of a negative‐pressure exam room to evaluate suspected walk‐in cases; streamlined testing access; provided post‐hospitalization telehealth visits to patients discharged with COVID‐19 (both with and without HIV); and served as an active site for COVID‐19 clinical trials.

3.2. Inpatient preparedness {#jia225573-sec-0009}
---------------------------

The Center operates a dedicated inpatient teaching "Immunology Service" (the Service) for admitted Center patients, staffed by Center faculty, with multidisciplinary Center staff coordination. With COVID‐19 hospitalizations, the Service was made aware of all COVID‐19 cases and provided an important link between admitted PWH and available COVID‐19 clinical trials. The Infectious Diseases Division, which encompasses the Service, enrolled COVID‐19 patients into two Phase 3 remdesivir clinical trials (ClinicalTrials.gov, NCT04292730, NCT04292899) and a convalescent plasma therapy study. The Center is also a site for an ambulatory study of azithromycin and hydroxychloroquine. Importantly, PWH were not excluded from these trials and the Service actively referred PWH to them. It is crucial that PWH enroll in such trials, as we offer potential life‐saving treatments, and learn whether HIV itself or HIV‐related immunosuppression predispose PWH to different clinical presentations, courses, or outcomes compared to persons without HIV, and whether ART provides protection from SARS‐CoV‐2.

3.3. Case series {#jia225573-sec-0010}
----------------

Between 30 March and 20 May, 27 RI PWH were diagnosed with COVID‐19 using nucleic acid‐based testing; 0.18% of COVID‐19 diagnoses in the state during that time period. Nine were hospitalized (Table [1](#jia225573-tbl-0001){ref-type="table"}) and 18 were outpatients (Table [2](#jia225573-tbl-0002){ref-type="table"}). Overall, patients' HIV was diagnosed between 1980 and 2019; 20 were male, six female and one transgender female, ages 30 to 71 years; 13/27 Hispanic and 6/27 African American; most were diagnosed with COVID‐19 in the outpatient or emergency department setting; and all had HIV VL \< 200 copies/mL and were on antiretroviral therapy with a CD4 count range 87 to 1441 cells/µL. Twenty‐six of the 27 had common COVID‐19 symptoms for one to twenty‐eight days and most had other co‐morbidities and/or risk factors, with no apparent differences between hospitalized and non‐hospitalized patients. Chest imaging, if obtained, ranged from normal X‐rays to computerized tomography multifocal airspace disease with ground glass infiltrates. Abnormal imaging findings were more common among hospitalized patients. The nine hospitalized patients (Table [1](#jia225573-tbl-0001){ref-type="table"}) were admitted for one to thirteen (average 8) days. Of those, three lived in nursing‐homes, three had O2 saturations \< 94% at presentation, six received remdesivir through a clinical trial or emergency use authorization, and none required intensive care unit admission. Most had COVID‐19‐associated laboratory abnormalities, reflecting lymphopenia and inflammation. Of the hospitalized patients, eight were discharged and one died. This patient had advanced metastatic renal cell carcinoma and goals of care focused on his comfort. Eighteen of the 27 were followed in the outpatient setting and did not require hospitalization (Table [2](#jia225573-tbl-0002){ref-type="table"}).

###### 

Inpatient HIV and SARS‐CoV‐2 coinfection in Rhode Island

                                                                   Patient 1                   Patient 2            Patient 3            Patient 4                             Patient 5                   Patient 6              Patient 7              Patient 8                      Patient 9
  ---------------------------------------------------------------- --------------------------- -------------------- -------------------- ------------------------------------- --------------------------- ---------------------- ---------------------- ------------------------------ ----------------------------
  General                                                                                                                                                                                                                                                                               
  Sex (gender)                                                     Male                        Male                 Male                 Male                                  Male                        Male                   Male (female)          Male                           Female
  Age (years)                                                      63                          52                   63                   43                                    59                          45                     39                     71                             60
  Race/ethnicity                                                   AA                          Hispanic             Hispanic             Hispanic                              AA                          Hispanic               Hispanic               White (non‐Hispanic)           White (non‐Hispanic
  HIV                                                                                                                                                                                                                                                                                   
  Dx year                                                          1989                        2005                 2011                 2010                                  2002                        2009                   2005                   1999                           1980's
  Current ART                                                      ABC/DTG/3TC                 EVG/c/FTC/TAF        EVG/c/FTC/TAF        EVG/c/FTC/TAF                         EFV, ABC                    EFV/FTC/TDF            BTG/FTC/TAF            ABC/DTG/3TC                    BTG/FTC/TAF
  VL (copies/mL)[^a^](#jia225573-note-0002){ref-type="fn"}         \<20                        \<20                 \<20                 \<20                                  \<20                        \<20                   \<20                   \<20                           \<20
  CD4 count[^a^](#jia225573-note-0002){ref-type="fn"} (cells/µL)   442                         567                  87                   700                                   936                         334                    835                    361                            1189
  CD4% [^a^](#jia225573-note-0002){ref-type="fn"}                  13                          31                   9                    42                                    42                          23                     33                     45                             56
  Time CD4\> 200                                                   Since 2011                  Since 2005           Never                Since 2011                            Since 2002                  Since 2010             Since 2008             Since 2003                     At least since 2008
  COVID‐19                                                                                                                                                                                                                                                                              
  Risk factors                                                     Nursing home with + cases   None                 None                 Recent travel                         Nursing home with + cases   Contact with + cases   Contact with + cases   Nursing home with + cases      Recent hospitalization
  Other Co‐morbidities                                             Dementia, CVA               Obesity, HTN         DM, HLD              None                                  Cancer, ESRD                None                   Obesity                Alcoholism                     COPD, Cocaine use, DM
  Active tobacco use                                               No (former smoker)          No                   No (former smoker)   Yes                                   No                          No                     No                     Yes                            Yes
  Symptoms                                                         SOB, lethargy               SOB, fever, HA       SOB                  SOB, cough, sore throat, chest pain   SOB                         SOB, HA                SOB, fever, HA         Lethargy, decreased appetite   SOB, fever, chills
  Symptoms pre‐testing                                             1 day                       8 days               28 days              14 days                               1 day                       8 days                 7 days                 7 days                         2 days
  Min RA O2%                                                       70%                         86%                  79%                  95%                                   94%                         94%                    94%                    95%                            85%
  ALC (10^9^/L)[^b^](#jia225573-note-0003){ref-type="fn"}          300                         600                  1300                 1370                                  500                         500                    1000                   600                            600
  CRP (mg/L)[^c^](#jia225573-note-0004){ref-type="fn"}             202                         102                  25                   4                                     N/A                         276                    296                    209                            134
  Ferritin (ng/mL)[^c^](#jia225573-note-0004){ref-type="fn"}       163                         3179                 500                  321                                   N/A                         1095                   1600                   804                            159
  D‐dimer(ng/mL)[^c^](#jia225573-note-0004){ref-type="fn"}         N/A                         514                  245                  252                                   N/A                         255                    189                    747                            N/A
  ALT (IU/L)[^c^](#jia225573-note-0004){ref-type="fn"}             72                          102                  62                   29                                    N/A                         113                    116                    3                              21
  AST IU/L)[^c^](#jia225573-note-0004){ref-type="fn"}              81                          76                   45                   31                                    N/A                         103                    50                     18                             25
  LDH (IU/L)[^c^](#jia225573-note-0004){ref-type="fn"}             154                         337                  236                  252                                   N/A                         468                    367                    147                            250
  HCV status                                                       Cured                       Neg                  Neg                  Neg                                   Neg                         Cleared                Neg                    Neg                            Cured
  Imaging                                                          CXR: bibasilar asd          CXR: bilateral asd   CXR: bilateral asd   CT mf ground glass infiltrates        CXR: diffuse BL asd         CXR: mf BL asd         CXR: BL asd            CXR: right asd                 CXR: emphysematous changes
  COVID‐19 therapy                                                 RDV (10 days)               RDV (8 days)         RDV (10 days)        No                                    No                          No                     RDV (4 days)           RDV (2 days)                   RDV (5 days)
  Time in hospital                                                 13 days                     8 days               13 days              6 days                                8 days                      1 day                  8 days                 4 days                         8 days
  Outcome                                                          DC                          DC                   DC                   DC                                    Died                        DC                     DC                     DC                             DC

/c, cobicistat; +, positive; 3TC, lamivudine; AA, African American; ABC, abacavir; ALC, absolute lymphocyte count; ART, antiretroviral therapy; asd, air space disease; BL, bilateral; BTG, bictegravir; CD4 count/VL are prior to SARS‐CoV‐2 infection; cong, congestion; CT, computerized tomography; CVA, cerebrovascular accident; CXR, chest X‐ray; DC, discharge; DM, diabetes mellitus, DRV, darunavir; DTG, dolutegravir; dx, diagnosis; ED, emergency department; EFV, efavirenz; ESRD, end stage renal disease; EVG, elvitegravir; FTC, emtricitabine; HA, headache; HCV, hepatitis C virus; HLD, hyperlipidaemia; HTN, hypertension; ICU, intensive care unit; IST, interstitial; mf, multifocal; Min, minimal; N/A, not available; Neg, negative; O2, oxygen; RA, room air; RDV, remdesivir; RPV, rilpivirine; RUL, right upper lobe; Sat, saturation; SOB, shortness of breath; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate, VL, viral load.

Before COVID‐19

lowest recorded

highest recorded.

John Wiley & Sons, Ltd

###### 

Outpatient HIV and SARS‐CoV‐2 coinfection in Rhode Island

                                                                    Pt 1                         Pt 2                    Pt 3                   Pt 4                         Pt 5                                Pt 6                           Pt 7                      Pt 8                  Pt 9            Pt 10                  Pt 11                  Pt 12                Pt 13                  Pt 14                   Pt 15                 Pt 16            Pt 17                 Pt 18
  ----------------------------------------------------------------- ---------------------------- ----------------------- ---------------------- ---------------------------- ----------------------------------- ------------------------------ ------------------------- --------------------- --------------- ---------------------- ---------------------- -------------------- ---------------------- ----------------------- --------------------- ---------------- --------------------- -------------------
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sex                                                               Male                         Male                    Female                 Female                       Male                                Male                           Male                      Male                  Female          Male                   Male                   Male                 Male                   Male                    Male                  Male             Female                Female
  Age (years)                                                       62                           37                      57                     51                           32                                  53                             48                        38                    37              57                     56                     44                   54                     37                      30                    42               47                    51
  Race/ethnicity                                                    White; non‐Hispanic          White; non‐Hispanic     Other                  Hispanic                     Hispanic                            White; non‐Hispanic            AA                        White; non‐Hispanic   AA              Hispanic               Hispanic               Hispanic             Hispanic               Hispanic                White; non‐Hispanic   Hispanic         AA                    AA
  HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dx year                                                           2015                         2012                    2015                   2001                         2012                                2009                           2002                      2013                  2015            2017                   2001                   2014                 2010                   2010                    2019                  2005             2009                  2017
  Current ART                                                       BTG/FTC/TAF                  BTG/FTC/TAF             BTG/FTC/TAF            DTG/RPV                      BTG/FTC/TAF                         EVG/c/FTC/TAF                  EVG/c/FTC/TAF             EVG/c/FTC/TAF         EVG/c/FTC/TAF   BTG/FTC/TAF            BTG/FTC/TAF            BTG/FTC/TAF          BTG/FTC/TAF            BTG/FTC/TAF             BTG/FTC/TAF           BTG/FTC/TAF      DVR/c/FTC/TAF         BTG/FTC/TAF
  VL (copies/mL)[^a^](#jia225573-note-0006){ref-type="fn"}          \<20                         69                      \<20                   \<20                         \<20                                \<20                           46                        \<20                  \<20            \<20                   \<20                   46                   \<20                   \<20                    \<20                  \<20             \<20                  \<20
  CD4 count [^a^](#jia225573-note-0006){ref-type="fn"} (cells/µL)   746                          789                     216                    746                          346                                 683                            1375                      760                   644             1441                   444                    357                  813                    638                     459                   743              347                   239
  CD4% [^a^](#jia225573-note-0006){ref-type="fn"}                   23                           35                      16                     21                           19                                  34                             35                        30                    27              53                     27                     14                   36                     32                      36                    18               32                    16
  Time CD4\> 200                                                    Since 2015                   Since 2017              Since 2015             Since 2012                   Since 2016                          Since 2010                     Since 2003                Since 2016            Since 2015      Since 2017             Since 2002             Since 2016           Since 2010             Since 2011              Since 2019            Since 2006       Since 2009            Since 2017
  COVID‐19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Risk factors                                                      Works in homeless Shelter    Contact with + cases    Contact with + cases   None                         Contact with + cases                Contact with + cases; travel   Contact with + cases      Healthcare worker     None            None                   Contact with + cases   Healthcare worker    Contact with + cases   Contact with + cases    None                  None             Works in group home   Healthcare worker
  Other Co‐morbidities                                              HTN                          Obesity                 DM                     DM, asthma                   HLH in remission, Histo‐plasmosis   HTN                            HTN                       Obesity               None            None                   HTN, obesity           Obesity              HTN, CAD               Alcoholism, cirrhosis   None                  None             None                  Obesity
  Active tobacco use                                                No                           No (former smoker)      No                     No (former smoker)           No (former smoker)                  Yes                            No                        No (former smoker)    No              No                     No                     No (former smoker)   No                     No (former smoker)      Yes                   No               No                    No
  Symptoms                                                          Cough, fever, low appetite   Cough, fever, myalgia   None                   Fever, myalgia, HA, chills   Fever, cough, sore throat           Anosmia, nasal cong            Fatigue, nasal cong, HA   Myalgia, back pain    HA              HA, myalgia, anosmia   HA, myalgia, anosmia   Myalgia, back pain   Lethargy, anosmia      SOB, fever, myalgia     Anosmia               Cough, myalgia   Fever, cough          HA, back pain
  Symptoms pre‐testing                                              14 days                      2 days                  N/A                    1 day                        3 days                              weeks                          4 days                    3 days                Unknown         7 days                 Unknown                5 days               Unknown                Unknown                 Unknown               9 days           Unknown               4 days
  Min RA O2%                                                        96%                          98%                     N/A                    98%                          N/A                                 N/A                            N/A                       N/A                   N/A             97%                    N/A                    95%                  N/A                    95%                     N/A                   N/A              N/A                   99%
  ALC (10^9^/L)[^b^](#jia225573-note-0007){ref-type="fn"}           2200                         800                     N/A                    1800                         N/A                                 N/A                            N/A                       N/A                   N/A             1400                   N/A                    2200                 N/A                    2100                    N/A                   N/A              N/A                   1600
  CRP (mg/L)[^c^](#jia225573-note-0008){ref-type="fn"}              N/A                          N/A                     N/A                    N/A                          N/A                                 N/A                            N/A                       N/A                   N/A             180                    N/A                    N/A                  N/A                    N/A                     N/A                   N/A              N/A                   N/A
  Ferritin (ng/mL)[^c^](#jia225573-note-0008){ref-type="fn"}        N/A                          N/A                     N/A                    N/A                          N/A                                 N/A                            N/A                       N/A                   N/A             412                    N/A                    N/A                  N/A                    N/A                     N/A                   N/A              N/A                   N/A
  D‐dimer (ng/mL)[^c^](#jia225573-note-0008){ref-type="fn"}         N/A                          N/A                     N/A                    N/A                          N/A                                 N/A                            N/A                       N/A                   N/A             142                    N/A                    N/A                  N/A                    N/A                     N/A                   N/A              N/A                   N/A
  ALT (IU/L)[^c^](#jia225573-note-0008){ref-type="fn"}              N/A                          14                      N/A                    25                           N/A                                 N/A                            N/A                       N/A                   N/A             24                     N/A                    N/A                  N/A                    61                      N/A                   N/A              N/A                   10
  AST IU/L)[^c^](#jia225573-note-0008){ref-type="fn"}               N/A                          31                      N/A                    21                           N/A                                 N/A                            N/A                       N/A                   N/A             30                     N/A                    N/A                  N/A                    71                      N/A                   N/A              N/A                   18
  LDH (IU/L)[^c^](#jia225573-note-0008){ref-type="fn"}              N/A                          N/A                     N/A                    N/A                          N/A                                 N/A                            N/A                       N/A                   N/A             245                    N/A                    N/A                  N/A                    N/A                     N/A                   N/A              N/A                   N/A
  HCV status                                                        Neg                          Neg                     Neg                    Neg                          Neg                                 Neg                            Neg                       Neg                   Neg             Neg                    Neg                    Neg                  Neg                    Neg                     Neg                   Neg              Cured                 Neg
  Imaging                                                           CXR: mild ist asd            CXR: clear lungs        N/A                    CXR: RUL asd                 N/A                                 N/A                            N/A                       N/A                   N/A             CXR: BL asd            N/A                    CXR: BL asd          N/A                    CXR: ist asd            N/A                   N/A              N/A                   Neg
  COVID‐19 therapy                                                  No                           No                      No                     No                           No                                  No                             No                        No                    No              No                     No                     No                   No                     No                      No                    No               No                    No
  Outcome                                                           DC from ED                   DC from ED              Home                   DC from ED                   Home                                Home                           Home                      Home                  Home            Home                   Home                   DC from ED           Home                   Home                    Home                  Home             Home                  Home

/c, cobicistat; +, positive; 3TC, lamivudine; AA, African American; ABC, abacavir; ALC, absolute lymphocyte count; ART, antiretroviral therapy; asd, air space disease; BL, bilateral; BTG, bictegravir; CD4 count/ VL are prior to COVID‐19 infection; cong, congestion; CT, computerized tomography; CVA, cerebrovascular accident; CXR, chest X‐ray; DC, discharge; DM, diabetes mellitus, DRV, darunavir; DTG, dolutegravir; dx, diagnosis; ED, emergency department; EFV, efavirenz; ESRD, end stage renal disease; EVG, elvitegravir; FTC, emtricitabine; HA, headache; HCV, hepatitis C virus; HLD, hyperlipidaemia; HLH, haemophagocytic lymphohistiocytosis; HTN, hypertension; ICU, intensive care unit; IST, interstitial; mf, multifocal; Min, minimal; N/A, not available; Neg, negative; O2, oxygen; Pt, patient; RA, room air; RDV, remdesivir; RPV, rilpivirine; RUL, right upper lobe; Sat, saturation; SOB, shortness of breath; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate, VL, viral load.

Before COVID‐19

lowest recorded

highest recorded.

John Wiley & Sons, Ltd

3.4. Case series highlights {#jia225573-sec-0011}
---------------------------

We highlight several unique points related to these 27 PWH and COVID‐19. First, the detailed description of the 27 RI patients adds to the limited HIV/SARS‐CoV‐2 coinfection literature. Patients had typical COVID‐19 symptoms like cough, shortness of breath, lethargy, fever, headache, sore throat, chest pain, myalgia and anosmia. Twenty were male, six female and one transgender female, most Hispanic or African American (including the one patient who died), with an average age 49 years. More than half recovered at home without requiring hospitalization. HIV VL was \<200 copies/mL for all, and with the exception of hospitalized patient \#3, all had CD4 count \>200 cells/µL. Taken together, despite concerns for higher COVID‐19 prevalence in PWH with CD4 counts \<200 or potentially poorer overall clinical outcomes in PWH, our data are consistent with reports from outside the US, suggesting that COVID‐19 is not more frequent among virologically suppressed PWH on ART. Additionally, clinical presentations, course and outcomes appear consistent with persons without HIV. It is still too early to draw any definitive conclusions from these few cases, and additional larger studies are needed.

Second, three patients, all hospitalized, lived in nursing‐homes with other residents with COVID‐19. All were initially asymptomatic; patient \#1 became acutely confused and hypoxic leading to hospitalization; patient \#5 was admitted for pain control in the setting of metastatic cancer, developed hypoxia and tachypnoea on hospital day 8, when he opted for comfort care and subsequently died; and patient \#8 was admitted for the complication of decreased oral intake and altered mental status. These cases highlight that nursing‐home residents were vulnerable to COVID‐19, likely because they were typically older, have co‐morbidities, live in close proximity to other at‐risk persons, and have prolonged interactions with caregivers, as described \[[17](#jia225573-bib-0017){ref-type="ref"}\]. Many reported individuals in these settings were asymptomatic at testing, as were our three patients, suggesting asymptomatic infection, with or without HIV \[[17](#jia225573-bib-0017){ref-type="ref"}\].

Third, we report the first six PWH and COVID‐19 in RI, adding to the two reported cases from Italy \[[12](#jia225573-bib-0012){ref-type="ref"}\] and Spain \[[10](#jia225573-bib-0010){ref-type="ref"}\], who received remdesivir. All six tolerated it well, including two with history of hepatitis C virus. In a preliminary report of a double‐blind, randomized, placebo‐controlled trial, remdesivir was recently shown to be superior to placebo in shortening the time to recovery in adults hospitalized with COVID‐19 and evidence of lower respiratory tract infection \[[18](#jia225573-bib-0018){ref-type="ref"}\]. We eagerly await the final results of ongoing clinical trials evaluating the safety and efficacy of remdesivir for COVID‐19, and it is essential and encouraging that PWH were included in these trials.

Fourth, whether and how HIV antiretrovirals impact acquisition or treatment of COVID‐19 remains unknown. Clinical trials to explore these possibilities are ongoing, for drugs such as tenofovir/emtricitabine, lopinavir/ritonavir and darunavir/cobicistat \[[19](#jia225573-bib-0019){ref-type="ref"}, [20](#jia225573-bib-0020){ref-type="ref"}, [21](#jia225573-bib-0021){ref-type="ref"}\]. A randomized, controlled, open‐label trial involving hospitalized adult patients with severe COVID‐19 showed no benefit of lopinavir‐ritonavir treatment beyond standard of care \[[22](#jia225573-bib-0022){ref-type="ref"}\]. All 27 PWH in this series were on antiretroviral therapy; 25/27 on emtricitabine or lamivudine; and 17/18 (94%) of outpatients and 6/9 (67%) of inpatients (*p* = 0.09; Fisher's Exact Test) on tenofovir formulations; suggesting that these antiretrovirals were not completely protective against SARS‐CoV‐2 infection. Whether ART medications have any impact on infection or outcomes remains to be determined.

Fifth, one RI patient with a CD4 count of 87 cells/µL presented with four weeks of progressive dyspnoea. He underwent bronchoscopy that ruled out *Pneumocystis jirovecii* pneumonia during a separate hospitalization four weeks before his COVID‐19 diagnosis. At that time, COVID‐19 was uncommon and he was not tested. Interestingly, a specimen from that bronchoscopy, subsequently tested, was positive for SARS‐CoV‐2. The patient had a prolonged 28‐day period before re‐hospitalization with respiratory symptoms and O2 saturations down to 79%, and his nasopharyngeal PCR testing remained positive at 38 days, which is on the longer end of the reported SARS‐CoV‐2 shedding range of eight to thirty‐seven days \[[1](#jia225573-bib-0001){ref-type="ref"}\]. Whether this prolonged symptomatology and PCR positivity is related to HIV infection, low CD4 count, ART, and/or other factors remains to be determined.

Lastly, with RIs aggressive rollout of ambulatory SARS‐CoV‐2 diagnostic testing, 162 Center patients were tested at the time data collection was completed, of whom the above 27 (17%) were found to be positive; Although this is currently higher than the statewide positivity rate (15,441 /170,739; 9%; *p* = 0.00002 chi square test) \[[15](#jia225573-bib-0015){ref-type="ref"}\], these numbers are subject to bias and should be interpreted cautiously, and broader testing, including of asymptomatic individuals and antibody testing, is still urgently needed.

4. CONCLUSIONS {#jia225573-sec-0012}
==============

We present a RI perspective, to our knowledge the largest detailed case series to date from the US, on HIV/SARS‐CoV‐2 coinfection. Despite being limited by a retrospective study design, small number of cases, limited testing early on and some unavailable data in times of telemedicine, this case series adds to limited global reports. Data are as yet inconclusive on the effect of the COVID‐19 pandemic on PWH \[[9](#jia225573-bib-0009){ref-type="ref"}, [10](#jia225573-bib-0010){ref-type="ref"}, [11](#jia225573-bib-0011){ref-type="ref"}, [12](#jia225573-bib-0012){ref-type="ref"}, [13](#jia225573-bib-0013){ref-type="ref"}, [14](#jia225573-bib-0014){ref-type="ref"}, [23](#jia225573-bib-0023){ref-type="ref"}, [24](#jia225573-bib-0024){ref-type="ref"}\]. More data on prevalence, clinical characteristics and outcomes of HIV/SARS‐CoV‐2 coinfection are needed to understand the existence of any differences between PWH and persons without HIV. Current guidance advises HIV providers on follow‐up (e.g. telehealth), practice management (e.g. staff support and triage) and medication needs (e.g. 90‐day supply) \[[25](#jia225573-bib-0025){ref-type="ref"}\]. These, as well as increased surveillance, testing and continued clinical follow‐up are critical as we develop our understanding of how HIV and antiretroviral therapy are affected by or have an impact on the COVID‐19 pandemic.
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